Latest prostate cancer treatment drug studies
Much of this research explores ways to reduce men's death rate by targeting castration-resistant prostate cancer.
Studies include new drugs such as
In addition, researchers work to develop new drugs against bone metastasis (see also modified citrus pectin) during the progression of castration-resistant prostate cancers, such as Src kinase inhibitors (Edwards J, Src kinase inhibitors: an emerging therapeutic option for prostate cancer, Expert Opin Investig Drugs, May 2010, p605-14).
All these latest prostate cancer treatment drug studies must proceed through lengthy trials before approval.
While docetaxel is currently approved, large phase III trials of sipuleucel-T and cabazitaxel have shown improved survival for patients leading to the approval of sipuleucel-T by the FDA in April 2010 (DiLorenzo G et al, Castration-resistant prostate cancer: current and emerging treatment strategies, Drugs May 2010, p983-1000).
Drugs may also prove to be valuable for both prevention (called chemoprevention) and treatments that target metabolic pathways governing lipid or glucose metabolism, and energy homeostasis, including FASN and AMPK (Plavin R et al, Metabolic alterations and targeted therapies in prostate cancer, Journal Pathol, January 2011, p284-95)..
Scientists are also working with non-drug natural sources like EGCG from green tea .
Can you really buy that doctor's guide to prostate cancer book for $0.01?
More health info with free subscription to the Green Tea Health Newsletter here:
This page last updated by Sharon Jones.
Subscribe now and don't miss a single issue.
Find out more!